Search hospitals > South Carolina > Greenville
Prisma Health Cancer Institute - Faris
Claim this profileGreenville, South Carolina 29605
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
322 reported clinical trials
8 medical researchers
Summary
Prisma Health Cancer Institute - Faris is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Faris is involved with conducting 322 clinical trials across 482 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Michael D. Zurenko.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside5 years of reported clinical research
Expert in Cancer
Expert in Tumors
94 reported clinical trials
192 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
58 reported clinical trials
119 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris7 years of reported clinical research
Studies Cancer
Studies Breast Cancer
26 reported clinical trials
64 drugs studied
Michael D. ZurenkoPrisma Health Cancer Institute - Eastside11 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
8 reported clinical trials
16 drugs studied
Clinical Trials running at Prisma Health Cancer Institute - Faris
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Colorectal Cancer
Tumors
Squamous Cell Carcinoma
Rectal Cancer
Colon Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Faris?
Prisma Health Cancer Institute - Faris is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Prisma Health Cancer Institute - Faris is involved with conducting 322 clinical trials across 482 conditions. There are 8 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Michael D. Zurenko.
Where is Prisma Health Cancer Institute - Faris located?
The Prisma Health Cancer Institute - Faris Hospital is located at 900 W. Faris Road, Greenville, SC 29605.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Prisma Health Cancer Institute–Faris Road:
- **Financial Assistance**: Visit the Prisma Health financial assistance page for general information.
- **Hospital Patient Accounts**: Call 864-454-9604 or toll-free 1-844-302-8298 for billing and insurance inquiries.
- **Physician Practice Patient Billing**: For billing questions, contact 864-797-6980 or toll-free 1-844-644-3160.
What insurance does Prisma Health Cancer Institute - Faris accept?
The Prisma Health Cancer Institute - Faris accepts a range of insurance plans such as Absolute Total Care - Ambetter, Absolute Total Care Medicaid, Aetna, Aetna Medicare, Allwell Medicare - Absolute Total Care, BCBS, BCBS Blue Cross, and UnitedHealthcare. It is recommended to directly contact the providers or facilities within the Institute to confirm the acceptance of specific insurance plans.
What awards or recognition has Prisma Health Cancer Institute - Faris received?
The Prisma Health Cancer Institute - Faris, located in Greenville, South Carolina, has received an $8.2 million award from the National Cancer Institute for outstanding research contributions through the National Cancer Institute Community Oncology Research Program. This institute is dedicated to the protection of human subjects in research, holding a Federalwide Assurance (FWA).